imm01-stem
Sarcopenic Obesity
Immunis, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Sarcopenic Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VITAMIN D Fondazione Policlinico Universitario Campus Bio-Medico | Phase 4 | BB |
Tirzepatide Pennington Biomedical Research Center | Phase 4 | BB |
Metformin VA Office of Research and Development | Phase 3 | B |
Oxytocin Sara Espinoza | Phase 1/2 | CCC |
Iodixanol Nemocnice AGEL Trinec-Podlesi a.s. | D |
Same molecule, other indications
imm01-stem is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →